ArticleCancer2019

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Alberto Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.